In addition, Sun et al. showed that, in a CH-induced PH murine model (11% O2 for 28 days), intratracheal in vivo administration of siRNA against TRPC1 attenuates pulmonary and RV arterial remodeling, with a significant reduction in right ventricular systolic pressure [185]. The gene discussed is TRPC1; the disease is cyclic hematopoiesis.